Axsome Therapeutics, Inc. Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

AXSM

株式のランク #2411
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
株価
$155.13
最終同期: 2026-10-19
時価総額
$8.13B
変化(1日)
-1.28%
変化(1年)
17.88%
国
US
取引 Axsome Therapeutics, Inc. (AXSM)

カテゴリー

Healthcare
Axsome Therapeutics, Inc.(AXSM)の配当利回りの履歴
Axsome Therapeutics, Inc.(銘柄コード: AXSM)の配当利回り(TTM)は2023-12-31時点で0.00%です。
過去5年間の平均配当利回り: 0.00%
Axsome Therapeutics, Inc.(AXSM)の2013から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
年 配当利回り 変化
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
類似企業または競合他社の配当利回り(TTM)